uBriGene Highlights Innovative Platforms at ISCT 2026

May 6, 2026

uBriGene to Present circRNA-LNP and Lentiviral Manufacturing Innovations at ISCT 2026 in Dublin

uBriGene Biosciences will participate in the ISCT 2026 Annual Meeting, taking place May 6–9 at the Convention Centre Dublin in Dublin. Organized by the International Society for Cell & Gene Therapy, the annual meeting is the largest global conference dedicated to translating cell and gene therapy breakthroughs into real-world clinical impact. With cutting-edge science, influential decision-makers, and global regulatory and industry leaders in attendance, ISCT is a key platform for advancing the future of advanced therapeutics.

Representing uBriGene at the meeting will be Dr. Xiulian Sun, b, and Mr. Qichen Li, Chief Executive Officer, who will engage with partners across the global cell and gene therapy ecosystem and present the company’s latest technological innovations supporting scalable advanced therapy development.

uBriGene will contribute to the scientific program with both an oral presentation and a poster presentation highlighting technologies designed to accelerate the development and manufacturing of advanced therapies

Oral Presentation - The Best-in-Class PBMC iPSC Reprogramming Kit via circRNA-LNP
Poster Presentation - Cost-Efficient, High-Yield cGMP Lentiviral Vector Manufacturing Using Suspension Culture, Ultra-T™ Technology, and Closed Downstream Processing

These presentations underscore uBriGene’s commitment to advancing scalable ATMP development and manufacturing, combining innovative technology platforms with client-focused services to help biotechnology companies translate scientific breakthroughs into therapies that reach patients faster.

Meet uBriGene at ISCT 2026

Researchers, biotech innovators, and pharmaceutical partners attending ISCT 2026 are invited to connect with the uBriGene team in Dublin.

Whether you are developing cell therapies, viral vectors, gene therapies, or RNA-based technologies, uBriGene provides integrated solutions spanning process development, GMP manufacturing, and scalable platform technologies.